CJC-1295 ipamorelin with retatrutide has no published human data. Learn how the three compounds differ, why the stack is untested, and what to ask a doctor.
CJC-1295 and ipamorelin are growth-hormone-releasing peptides sold as research chemicals, while retatrutide is an investigational triple-agonist weight loss drug that the FDA has not approved. No published human study has tested all three compounds together, so there is no validated dose, schedule, or safety profile for this combination. The three products work through different pathways and sit at very different stages of research.
What Each Compound Does
These compounds are grouped together in online discussions because all three are linked to body composition, not because they share a mechanism.
- CJC-1295 is a modified growth hormone-releasing hormone (GHRH) analog. The DAC version binds to albumin in the bloodstream and stays active for roughly six to eight days, while the version without DAC clears in about 30 minutes.
- Ipamorelin is a selective ghrelin-receptor agonist that prompts a pulse of growth hormone release. In early research models it raised growth hormone without large spikes in cortisol or prolactin.
- Retatrutide is a once-weekly injectable that activates three receptors at the same time: GLP-1, GIP, and glucagon. Eli Lilly is developing it, and it remains in Phase 3 trials.
People who search what is cjc-1295 ipamorelin are usually asking about the pairing rather than a single product. CJC-1295 supplies the GHRH signal, ipamorelin supplies the ghrelin signal, and the two are studied together because they act on separate receptors that both feed into growth hormone release.
The CJC-1295 and Ipamorelin Pairing
For most people, the cjc 1295 with ipamorelin peptide combination is the entry point into GH-focused research. Enthusiasts describe it as a way to support pulsatile growth hormone release, but the human data behind that claim is limited and short-term.
One common decision is which form of CJC-1295 to use. People comparing cjc-1295 ipamorelin with dac or without are usually choosing between a once-weekly injection and a daily one timed around sleep or fasting. Any cjc-1295 dac with ipamorelin dosage chart circulating online is anecdotal, because no regulator has approved a dosing schedule for human use.
Comparisons like cjc-1295 ipamorelin vs tesamorelin come up often as well. Tesamorelin is an FDA-approved GHRH analog, but its approval is narrow: it is indicated for excess abdominal fat in people living with HIV and lipodystrophy, while CJC-1295 has no approved human indication at all.
Where Retatrutide Fits, and Why It Is Different
Retatrutide belongs to the same broad family as semaglutide and tirzepatide, with an added glucagon receptor component. In a Phase 2 trial published in 2023, participants who received the highest dose lost roughly a quarter of their body weight over 48 weeks.
That result is about appetite and food intake, not growth hormone. GH secretagogues act on growth hormone and IGF-1 signaling, and ghrelin-pathway compounds can sometimes increase hunger rather than suppress it. The overlap between retatrutide and a CJC-1295/ipamorelin stack is mostly a shared conversation about body composition, not shared biology.
Is the Three-Part Stack Studied in Humans?
No. There is no published human trial that combines a GHRH analog, a ghrelin mimetic, and a triple GLP-1/GIP/glucagon agonist. Everything written about cjc 1295 ipamorelin and retatrutide is extrapolated from separate studies of each compound alone.
The theoretical interaction points are worth taking seriously:
- Retatrutide slows gastric emptying and shifts how the body handles glucose, and growth hormone plus IGF-1 also influence insulin sensitivity.
- GLP-1 class drugs and GH secretagogues can both cause fluid retention, nausea, headache, or injection-site reactions.
- Adding compounds multiplies the variables a clinician would have to untangle if a side effect appeared.
Other popular peptide pairings, such as bpc-157 and cjc-1295 together or an igf-1 lr3 cjc 1295 ipamorelin stack, raise the same problem. Each addition increases the number of unknowns without adding human safety data.
Side-by-Side Comparison
| Compound | Mechanism | Half-Life | Typical Research Route | FDA Status |
|---|---|---|---|---|
| CJC-1295 with DAC | GHRH receptor agonist | About 6-8 days | Subcutaneous, weekly | Not approved |
| CJC-1295 without DAC | GHRH receptor agonist | About 30 minutes | Subcutaneous, daily | Not approved |
| Ipamorelin | Selective ghrelin receptor agonist | About 2 hours | Subcutaneous, daily | Not approved |
| Retatrutide | Triple GLP-1, GIP, and glucagon agonist | About 6 days | Subcutaneous, weekly | Investigational (Phase 3) |
Safety, Sourcing, and Legal Status
CJC-1295 and ipamorelin are not FDA-approved for human use in the United States. Most products sold online are labeled "for research use only," which means they have not been verified for purity, sterility, or accurate dosing.
Retatrutide is not FDA-approved either. It is legally available only through enrollment in a clinical trial, so vials sold as retatrutide on the gray market are unregulated and may not contain the drug at all.
Reported side effects from GH secretagogues include water retention, joint aches, tingling in the hands, and changes in blood sugar. Retatrutide's trial side effects were mostly gastrointestinal, including nausea, diarrhea, and vomiting, and they tended to increase with dose.
What to Ask a Healthcare Professional
Anyone considering these compounds should talk with a licensed clinician who knows their history, current medications, and lab work. Useful questions include:
- Could a GH secretagogue interact with a GLP-1 or triple-agonist medication I already take?
- Do my glucose, IGF-1, and thyroid labs suggest any reason to avoid these compounds?
- Which symptoms would mean I should stop and seek care right away?
If the underlying goal is weight management, FDA-approved options exist and are supported by far more evidence than any research peptide stack. If the goal relates to growth hormone, an endocrinologist can determine whether a diagnosable condition is even present. Self-directed use of unapproved injectables carries risks that no forum thread can quantify.
Frequently Asked Questions
Can you stack CJC-1295 and ipamorelin with retatrutide?
No published human study has tested that three-part combination, so there is no known safe dose or schedule for it. Each compound acts on different hormone pathways, and the interactions between them have never been formally evaluated. Talk with a licensed healthcare professional before combining any of them.
Is retatrutide FDA-approved?
No. Retatrutide is still in Phase 3 clinical trials and is not approved for any indication. Outside of a trial, products marketed as retatrutide are unregulated and may not contain the drug described on the label.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
The DAC version binds to albumin in the blood, which extends its activity to roughly six to eight days. CJC-1295 without DAC, often sold as mod GRF 1-29, is active for only about 30 minutes and is typically handled with more frequent injections in research settings. Neither form is FDA-approved for human use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.